These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 37204656)

  • 1. An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
    Zhou XD; Targher G; Byrne CD; Somers V; Kim SU; Chahal CAA; Wong VW; Cai J; Shapiro MD; Eslam M; Steg PG; Sung KC; Misra A; Li JJ; Brotons C; Huang Y; Papatheodoridis GV; Sun A; Yilmaz Y; Chan WK; Huang H; Méndez-Sánchez N; Alqahtani SA; Cortez-Pinto H; Lip GYH; de Knegt RJ; Ocama P; Romero-Gomez M; Fudim M; Sebastiani G; Son JW; Ryan JD; Ikonomidis I; Treeprasertsuk S; Pastori D; Lupsor-Platon M; Tilg H; Ghazinyan H; Boursier J; Hamaguchi M; Nguyen MH; Fan JG; Goh GB; Al Mahtab M; Hamid S; Perera N; George J; Zheng MH
    Hepatol Int; 2023 Aug; 17(4):773-791. PubMed ID: 37204656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.
    Zhang L; El-Shabrawi M; Baur LA; Byrne CD; Targher G; Kehar M; Porta G; Lee WS; Lefere S; Turan S; Alisi A; Weiss R; Faienza MF; Ashraf A; Sundaram SS; Srivastava A; De Bruyne R; Kang Y; Bacopoulou F; Zhou YH; Darma A; Lupsor-Platon M; Hamaguchi M; Misra A; Méndez-Sánchez N; Ng NBH; Marcus C; Staiano AE; Waheed N; Alqahtani SA; Giannini C; Ocama P; Nguyen MH; Arias-Loste MT; Ahmed MR; Sebastiani G; Poovorawan Y; Al Mahtab M; Pericàs JM; Reverbel da Silveira T; Hegyi P; Azaz A; Isa HM; Lertudomphonwanit C; Farrag MI; Nugud AAA; Du HW; Qi KM; Mouane N; Cheng XR; Al Lawati T; Fagundes EDT; Ghazinyan H; Hadjipanayis A; Fan JG; Gimiga N; Kamal NM; Ștefănescu G; Hong L; Diaconescu S; Li M; George J; Zheng MH
    Med; 2024 Jul; 5(7):797-815.e2. PubMed ID: 38677287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
    Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.
    Cheng PN; Chen WJ; Hou CJ; Lin CL; Chang ML; Wang CC; Chang WT; Wang CY; Lin CY; Hung CL; Peng CY; Yu ML; Chao TH; Huang JF; Huang YH; Chen CY; Chiang CE; Lin HC; Li YH; Lin TH; Kao JH; Wang TD; Liu PY; Wu YW; Liu CJ
    Clin Mol Hepatol; 2024 Jan; 30(1):16-36. PubMed ID: 37793641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
    Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
    J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
    Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
    Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
    Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
    Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
    Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
    Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
    HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
    Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
    Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease.
    Badmus OO; Hinds TD; Stec DE
    Curr Hypertens Rep; 2023 Aug; 25(8):151-162. PubMed ID: 37191842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.